

Keratoconjunctivitis Sicca (Dry Eye) - Pipeline Review, H2 2018

URL:	https://marketpublishers.com/r/K027992FEFDEN.html
Date:	September 18, 2018
Pages:	228
Price:	US\$ 2,000.00
ID:	K027992FEFDEN

Keratoconjunctivitis Sicca (Dry Eye) - Pipeline Review, H2 2018

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Keratoconjunctivitis Sicca (Dry Eye) - Pipeline Review, H2 2018, provides an overview of the Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) pipeline landscape.

Keratoconjunctivitis sicca (KCS) or dry eye disease (DED) or dry eye syndrome (DES) is a condition in which a person experience desiccation of the conjunctiva and cornea due to an inadequate tear film. Symptoms include hyperemia, mucoid discharge, ocular irritation, photophobia and blurry vision. Risk factors include age, wearing contact lenses and low levels of vitamin A. Treatment includes artificial tear substitutes, topical anti-inflammatory agents, secretagogues and immunosuppressants.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Keratoconjunctivitis Sicca (Dry Eye) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Keratoconjunctivitis Sicca (Dry Eye) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 8, 31, 5, 1, 32, 4 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

- The pipeline guide provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology)

REASONS TO BUY

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Content

Introduction

Keratoconjunctivitis Sicca (Dry Eye) - Overview

Keratoconjunctivitis Sicca (Dry Eye) - Therapeutics Development

Keratoconjunctivitis Sicca (Dry Eye) - Therapeutics Assessment

Keratoconjunctivitis Sicca (Dry Eye) - Companies Involved in Therapeutics Development

Keratoconjunctivitis Sicca (Dry Eye) - Drug Profiles

Keratoconjunctivitis Sicca (Dry Eye) - Dormant Projects

Keratoconjunctivitis Sicca (Dry Eye) - Discontinued Products

Keratoconjunctivitis Sicca (Dry Eye) - Product Development Milestones

Appendix

LIST OF TABLES

Number of Products under Development for Keratoconjunctivitis Sicca (Dry Eye), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Number of Products under Development by Companies, H2 2018 (Contd.3), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Products under Development by Companies, H2 2018 (Contd.3), H2 2018
Products under Development by Companies, H2 2018 (Contd.4), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Target, H2 2018 (Contd.1), H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018 (Contd.1), H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Aldeyra Therapeutics Inc, H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Allergan Plc, H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Ascendia Pharmaceuticals LLC, H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Aurinia Pharmaceuticals Inc, H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by BioLineRx Ltd, H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Cambium Medical Technologies LLC, H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Clementia Pharmaceuticals Inc, H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Dompe Farmaceutici SpA, H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by HanAll Biopharma Co Ltd, H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Huons Global Co Ltd, H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Icure Pharmaceutical Inc, H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Kala Pharmaceuticals Inc, H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Kukje Pharmaceutical Industry Co Ltd, H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Kv1.3 Therapeutics, H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Laboratoires Thea SA, H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Laboratorios Sophia SA de CV, H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Merck & Co Inc, H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Mitotech SA, H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Nanomerics Ltd, H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Nemus Bioscience Inc, H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Novaliq GmbH, H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Ocular Therapeutix Inc, H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Oculis ehf, H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Ocunova LLC, H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by OncoNOx ApS, H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Otsuka Holdings Co Ltd, H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Palatin Technologies Inc, H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Pharmaleads SA, H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Quorum Innovations LLC, H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Redwood Pharma AB, H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by RegeneRx Biopharmaceuticals Inc, H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Samjin Pharm Co Ltd, H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Santen Pharmaceutical Co Ltd, H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Senju Pharmaceutical Co Ltd, H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Shire Plc, H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Sylentis SAU, H2 2018

Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Tetra Bio-Pharma Inc, H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by TopiVert Ltd, H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Vanda Pharmaceuticals Inc, H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Xigen SA, H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Dormant Projects, H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Dormant Projects, H2 2018 (Contd.1), H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Dormant Projects, H2 2018 (Contd.2), H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Dormant Projects, H2 2018 (Contd.3), H2 2018
Keratoconjunctivitis Sicca (Dry Eye) - Discontinued Products, H2 2018

LIST OF FIGURES

Number of Products under Development for Keratoconjunctivitis Sicca (Dry Eye), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

COMPANIES MENTIONED

Aldeyra Therapeutics Inc
Allergan Plc
Ascendia Pharmaceuticals LLC
Aurinia Pharmaceuticals Inc
BioLineRx Ltd
Cambium Medical Technologies LLC
Clementia Pharmaceuticals Inc
Dompe Farmaceutici SpA
HanAll Biopharma Co Ltd
Huons Global Co Ltd
Icure Pharmaceutical Inc
Kala Pharmaceuticals Inc
Kukje Pharmaceutical Industry Co Ltd
Kv1.3 Therapeutics
Laboratoires Thea SA
Laboratorios Sophia SA de CV
Lee's Pharmaceutical Holdings Ltd
Merck & Co Inc
Mitotech SA
Nanomerics Ltd
Nemus Bioscience Inc
Novaliq GmbH
Ocular Therapeutix Inc
Oculus ehf
Ocunova LLC
OncoNOx ApS
Otsuka Holdings Co Ltd
Palatin Technologies Inc
Pharmaleads SA
Quorum Innovations LLC

Redwood Pharma AB
RegeneRx Biopharmaceuticals Inc
Samjin Pharm Co Ltd
Santen Pharmaceutical Co Ltd
Senju Pharmaceutical Co Ltd
Shire Plc
Sylentis SAU
Tetra Bio-Pharma Inc
TopiVert Ltd
Vanda Pharmaceuticals Inc
Xigen SA

I would like to order:

Product name: Keratoconjunctivitis Sicca (Dry Eye) - Pipeline Review, H2 2018
Product link: <https://marketpublishers.com/r/K027992FEFDEN.html>
Product ID: K027992FEFDEN
Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service: office@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <https://marketpublishers.com/r/K027992FEFDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
E-mail:
Company:
Address:
City:
Zip/Post Code:
Country:
Tel:
Fax:
Your message:

* All fields are required

Customer Signature _____

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms_conditions.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**